Chronic pharmacological activation of P2Y13 receptor in mice decreases HDL-cholesterol level by increasing hepatic HDL uptake and bile acid secretion

Singh, 2007, High-density lipoprotein as a therapeutic target: a systematic review, JAMA, 298, 786, 10.1001/jama.298.7.786

von Eckardstein, 2005, Current understanding of the metabolism and biological actions of HDL, Curr. Opin. Clin. Nutr. Metab. Care, 8, 147, 10.1097/00075197-200503000-00007

Rothblat, 2010, High-density lipoprotein heterogeneity and function in reverse cholesterol transport, Curr. Opin. Lipidol., 21, 229, 10.1097/MOL.0b013e328338472d

Trigatti, 2000, The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism, Curr. Opin. Lipidol., 11, 123, 10.1097/00041433-200004000-00004

Martinez, 2003, Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis, Nature, 421, 75, 10.1038/nature01250

Jacquet, 2005, The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis, Cell. Mol. Life Sci., 62, 2508, 10.1007/s00018-005-5194-0

Malaval, 2009, RhoA/ROCK I signalling downstream of the P2Y13 ADP-receptor controls HDL endocytosis in human hepatocytes, Cell. Signal., 21, 120, 10.1016/j.cellsig.2008.09.016

Gachet, 2008, P2 receptors, platelet function and pharmacological implications, Thromb. Haemost., 99, 466, 10.1160/TH07-11-0673

Storey, 2011, Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors, Thromb. Haemost., 105, S75, 10.1160/THS10-12-0769

Fabre, 2010, P2Y13 receptor is critical for reverse cholesterol transport, Hepatology, 52, 1477, 10.1002/hep.23897

Trigatti, 2003, Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 23, 1732, 10.1161/01.ATV.0000091363.28501.84

Storey, 2001

Bligh, 1959, A rapid method of total lipid extraction and purification, Can. J. Biochem. Physiol., 37, 911, 10.1139/o59-099

Vieu, 1996, Identification and quantitation of diacylglycerols in HDL and accessibility to lipase, J. Lipid Res., 37, 1153, 10.1016/S0022-2275(20)42024-3

Barbaras, 1994, Specific binding of free apolipoprotein A-I to a high-affinity binding site on HepG2 cells: characterization of two high-density lipoprotein sites, Biochemistry, 33, 2335, 10.1021/bi00174a047

Kunnen, 2012, Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?, J. Lipid Res., 53, 1783, 10.1194/jlr.R024513

Wang, 1998, Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice, J. Biol. Chem., 273, 32920, 10.1074/jbc.273.49.32920

Ueda, 1999, Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice, J. Biol. Chem., 274, 7165, 10.1074/jbc.274.11.7165

Silver, 2001, High density lipoprotein (hdl) particle uptake mediated by scavenger receptor class b type 1 results in selective sorting of hdl cholesterol from protein and polarized cholesterol secretion, J. Biol. Chem., 276, 25287, 10.1074/jbc.M101726200

Van Eck, 2003, Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver, J. Biol. Chem., 278, 23699, 10.1074/jbc.M211233200

Nieland, 2005, Endocytosis is not required for the selective lipid uptake mediated by murine SR-BI, Biochim. Biophys. Acta, 1734, 44, 10.1016/j.bbalip.2005.02.007

Sun, 2006, Quantitative analysis of SR-BI-dependent HDL retroendocytosis in hepatocytes and fibroblasts, J. Lipid Res., 47, 1700, 10.1194/jlr.M500450-JLR200

Goldstein, 2006, Protein sensors for membrane sterols, Cell, 124, 35, 10.1016/j.cell.2005.12.022

Kozarsky, 1997, Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels, Nature, 387, 414, 10.1038/387414a0

Wiersma, 2009, Scavenger receptor class B type I mediates biliary cholesterol secretion independent of ATP-binding cassette transporter g5/g8 in mice, Hepatology, 50, 1263, 10.1002/hep.23112

Hişmioğullari, 2007, Biliary lipid secretion, Turk. J. Gastroenterol., 18, 65

El Bouhassani, 2011, Cholesteryl ester transfer protein expression partially attenuates the adverse effects of SR-BI receptor deficiency on cholesterol metabolism and atherosclerosis, J. Biol. Chem., 286, 17227, 10.1074/jbc.M111.220483

Joy, 2008, Is raising HDL a futile strategy for atheroprotection?, Nat. Rev. Drug Discov., 7, 143, 10.1038/nrd2489

Gutstein, 2012, Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction, Clin. Pharmacol. Ther., 91, 109, 10.1038/clpt.2011.271

Kontush, 2008, Spotlight on HDL-raising therapies: insights from the torcetrapib trials, Nat. Clin. Pract. Cardiovasc. Med., 5, 329, 10.1038/ncpcardio1191

Rhainds, 2012, An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels, Future Cardiol., 8, 513, 10.2217/fca.12.25

Nicholls, 2008, HDL: still a target for new therapies?, Curr. Opin. Investig. Drugs, 9, 950

Francis, 2010, The complexity of HDL, Biochim. Biophys. Acta, 1801, 1286, 10.1016/j.bbalip.2010.08.009